Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors

British Journal of Pharmacology

Volumn 172, Issue 16, 2015, Pages 4200-4215

  Harrison, Ian F ^a,b   Crum, William R ^c   Vernon, Anthony C ^c   Dexter, David T ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; NEUROTROPHIC FACTOR; PROTEIN BCL 2; VALPROIC ACID; ACETYLCYSTEINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; LACTACYSTIN; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EPIGENETICS; HEMISPHERE; HISTONE ACETYLATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOCOMOTION; LOW DRUG DOSE; MALE; MOLECULAR BIOLOGY; MORPHOLOGY; MOTOR DYSFUNCTION; NEUROLOGICAL AND SENSORIAL PROCEDURES; NEUROPROTECTION; NEURORESTORATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA PARS COMPACTA; SYSTEMIC THERAPY; UPREGULATION; ACETYLATION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLATION; ACETYLCYSTEINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE INHIBITORS; HISTONES; MALE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS, SPRAGUE-DAWLEY; UP-REGULATION; VALPROIC ACID;

EID: 84937517004     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13208     Document Type: Article

References (63)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
2. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK, (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138: 155-175.
3. Ammal Kaidery N, Tarannum S, Thomas B, (2013). Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities. Neurother 10: 698-708.
4. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E, (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
5. Britain BMAatRPSoG (2009). British National Formulary, 58 edn. BMJ Publishing Group: London.
6. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ, (1999). Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 18: 32-42.
7. Carman LS, Gage FH, Shults CW, (1991). Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 553: 275-283.
8. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RDS, (2012). Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 229: 208-215.
9. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, etal. (2006). Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11: 1116-1125.
10. Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T, (2009). Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
11. Crum WR, Giampietro VP, Smith EJ, Gorenkova N, Stroemer RP, Modo M, (2013a). A comparison of automated anatomical-behavioural mapping methods in a rodent model of stroke. J Neurosci Methods 218: 170-183.
12. Crum WR, Modo M, Vernon AC, Barker GJ, Williams SCR, (2013b). Registration of challenging pre-clinical brain images. J Neurosci Methods 216: 62-77.
13. Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, Zhao J, etal. (2010). Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS ONE 5: e11383.
14. Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, etal. (2011). a-Synuclein sequesters dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem 286: 9031-9037.
15. Dexter DT, Jenner P, (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62: 132-144.
16. Dietz KC, Casaccia P, (2010). HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 62: 11-17.
17. Duncan GW, Firbank MJ, O'Brien JT, Burn DJ, (2013). Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease? Mov Disord 28: 425-438.
18. Durrenberger PF, Fernando FS, Magliozzi R, Kashefi SN, Bonnert TP, Ferrer I, etal. (2012). Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol 124: 893-903.
19. FDA (2005). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Silver Spring, MD.
20. Genovese CR, Lazar NA, Nichols T, (2002). Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15: 870-878.
21. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, etal. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
22. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS, (2004). Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086.
23. Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I, (2008). Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 17: 169-184.
24. Harrison IF, Dexter DT, (2013). Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther 140: 34-52.
25. Hegarty SV, O'Keeffe GW, Sullivan AM, (2014). Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Neural Regen Res 9: 1708-1711.
26. Jenner P, Olanow CW, (2006). The pathogenesis of cell death in Parkinson's disease. Neurology 66 (10 Suppl 4): S24-S36.
27. Kazantsev AG, Thompson LM, (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7: 854-868.
28. Kidd SK, Schneider JS, (2010). Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res 1354: 172-178.
29. Kidd SK, Schneider JS, (2011). Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 194: 189-194.
30. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.
31. Kim HJ, Rowe M, Ren M, Hong J-S, Chen P-S, Chuang D-M, (2007). Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321: 892-901.
32. Kontopoulos E, Parvin JD, Feany MB, (2006). a-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15: 3012-3023.
33. Kordower JH, Bjorklund A, (2013). Trophic factor gene therapy for Parkinson's disease. Mov Disord 28: 96-109.
34. Lee JY, Kim HS, Choi HY, Oh TH, Ju BG, Yune TY, (2012). Valproic acid attenuates blood-spinal cord barrier disruption by inhibiting matrix metalloprotease-9 activity and improves functional recovery after spinal cord injury. J Neurochem 121: 818-829.
35. Löscher W, (2002). Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16: 669-694.
36. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
37. McNaught KSP, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW, (2002). Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13: 1437-1441.
38. Monti B, Polazzi E, Batti L, Crochemore C, Virgili M, Contestabile A, (2007). Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death. J Neurochem 103: 518-530.
39. Monti B, Polazzi E, Contestabile A, (2009). Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2: 95-109.
40. Monti B, Gatta V, Piretti F, Raffaelli S, Virgili M, Contestabile A, (2010). Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of α-synuclein. Neurotox Res 17: 130-141.
41. Monti B, Mercatelli D, Contestabile A, (2012). Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for parkinson's disease. HOAJ Biol 1: 4.
42. Niu C, Mei J, Pan Q, Fu X, (2009). Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact Funct Neurosurg 87: 69-81.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-D1106.
44. Paxinos G, Watson C, (2009). The Rat Brain in Stereotaxic Coordinates, 6th edn. Academic Press: New York.
45. Peng G-S, Li G, Tzeng N-S, Chen P-S, Chuang D-M, Hsu Y-D, etal. (2005). Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 134: 162-169.
46. Perucca E, (2002). Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16: 695-714.
47. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS, (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
48. Pienaar IS, Harrison IF, Elson JL, Bury A, Woll P, Simon AK, etal. (2015). An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease. Brain Struct Funct 220: 479-500.
49. Prediger R, Aguiar AJ, Moreira E, Matheus F, Castro A, Walz R, etal. (2011). The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des 17: 489-507.
50. Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, etal. (2013). Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease. PLoS ONE 8: e60012.
51. Riederer P, Wuketich S, (1976). Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301.
52. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler J-P, Boutillier A-L, (2003). Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 22: 6537-6549.
53. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST, (2000). CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39: 777-787.
54. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M, (1997). a-Synuclein in Lewy bodies. Nature 388: 839-840.
55. Ungerstedt U, Arbuthnott GW, (1970). Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
56. Vernon A, Johansson S, Modo M, (2010a). Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci 11: 1.
57. Vernon AC, Ballard C, Modo M, (2010b). Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Brain Res Rev 65: 28-55.
58. Vernon AC, Crum WR, Johansson SM, Modo M, (2011). Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS ONE 6: e17269.
59. Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SCR, etal. (2012). Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry 71: 855-863.
60. Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, etal. (2013). Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry 75: 982-990.
61. West MJ, Slomianka L, Gundersen HJG, (1991). Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
62. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang C-C, etal. (2008). Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11: 1123-1134.
63. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, etal. (2007). Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844.